On Oct 30, 2025, ARDX reported earnings of 0.00 USD per share (EPS) for Q3 25, beating the estimate of -0.05 USD, resulting in a 100.00% surprise. Revenue reached 110.33 million, compared to an expected 103.54 million, with a 6.55% difference. The market reacted with a +20.96% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 13 analysts forecast an EPS of 0.01 USD, with revenue projected to reach 120.65 million USD, implying an -- of --% EPS, and increase of 9.36% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Takeda Pharmaceutical Company Limited - ADR
Report Date
Jan 30, 2026 For Q3 26
Estimate
$34.44
Actual
$65.64
Surprise
+90.61%
FAQ
What were Ardelyx, Inc.'s earnings and revenue for the latest quarter Q3 2025?
For Q3 2025, Ardelyx, Inc. reported EPS of $0.00, beating estimates by 100%, and revenue of $110.33M, 6.55% above expectations.
How did the market react to Ardelyx, Inc.'s Q3 2025 earnings?
The stock price moved up 20.96%, changed from $5.01 before the earnings release to $6.06 the day after.
When is Ardelyx, Inc. expected to report next?
The next earning report is scheduled for Feb 19, 2026.
What are the forecasts for Ardelyx, Inc.'s next earnings report?
Based on 13
analysts, Ardelyx, Inc. is expected to report EPS of $0.01 and revenue of $120.65M for Q4 2025.